Thomsen T, Bickel U, Fischer J P, Kewitz H
Institut für Klinische Pharmacologie, FU-Berlin, Klinikum Steglitz, FRG.
Eur J Clin Pharmacol. 1990;39(6):603-5. doi: 10.1007/BF00316106.
The effect of galanthamine (GAL) and its 2 major metabolites on human cholinesterases has been explored. Epigalanthamine, a diastereomer of GAL, was 130-times less potent in vitro in its effect on acetylcholinesterase (AChE) in erythrocytes than the parent compound, and it did not differ significantly from the ketone galanthaminone. In vivo, the maximal 36-55% inhibition of AChE was approached 30 min after oral administration of 10 mg GAL. The duration of the catalytic inhibition corresponded to an elimination half-life of approximately 5-7 h. GAL was well tolerated in 8/8 healthy volunteers, and 3/4 Alzheimer patients tolerated the drug up to a daily dose of 40 mg.
已对加兰他敏(GAL)及其2种主要代谢产物对人胆碱酯酶的作用进行了研究。表加兰他敏是GAL的非对映异构体,其在体外对红细胞乙酰胆碱酯酶(AChE)的作用效力比母体化合物低130倍,且与酮类加兰他敏酮无显著差异。在体内,口服10 mg GAL后30分钟,AChE的最大抑制率接近36 - 55%。催化抑制的持续时间相当于消除半衰期约5 - 7小时。8名健康志愿者中有8名对GAL耐受性良好,4名阿尔茨海默病患者中有3名能耐受高达每日40 mg的药物剂量。